The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | The value of ctDNA in Hodgkin lymphoma: diagnosis, response assessment & more
Jonathan Friedberg, MD, MMSc, University of Rochester, Rochester, NY, discusses the potential of circulating tumor DNA (ctDNA) in Hodgkin lymphoma. Dr Friedberg emphasizes the value of using ctDNA in diagnosis and response assessment, highlighting findings from the S1826 trial (NCT03907488), which found a correlation between early clearance of ctDNA and progression-free survival. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
